The International Consortium for Innovation and Quality (IQ) Physiologically Based Pharmacokinetic modeling (PBPK) Induction Working Group (IWG) conducted a survey across participating companies around general strategies for PBPK modeling of induction, including experience with its utility to address various questions, regulatory interactions, and regulatory acceptance. The results highlight areas where PBPK modeling is used with high confidence and identify opportunities where confidence is lower and further evaluation is needed. To enhance the survey results, the PBPK-IWG also collected case studies and analyzed recent literature examples where PBPK models were applied to predict CYP3A induction-mediated drug-drug interactions. PBPK modeling of induction has evolved and progressed significantly proving to have great potential to accelerate drug discovery and development. With the aim of enabling optimal use for new molecular entities that are either substrates and/or inducers of CYP3A, the PBPK-IWG proposes initial workflows for PBPK application, discusses future trends, and identifies gaps that need to be addressed.
By Niresh Hariparsad, Diane Ramsden, Kunal Taskar, Justine Badée, Karthik Venkatakrishnan, Micaela B. Reddy, Tamara Cabalu, Dwaipayan Mukherjee, Jessica Rehmel, Jayaprakasam Bolleddula, Arian Emami Riedmaier, Chandra Prakash, Hugues Chanteux, Jialin Mao, Kenichi Umehara, Kushal Shah, Loeckie De Zwart, Martin Dowty, Masakatsu Kotsuma, Mengyao Li, Venkatesh Pilla Reddy, Dermot F. McGinnity, Neil Parrott